In their study, Halle and colleagues found that lymph node negative cervical cancer patients with high expression of ectodomain EGFR isoforms had a high probability of relapse after chemoradiotherapy, whereas the EGFR tyrosine kinase activity was of minor importance. Gene expression profiles of the tumors were used to further explore these findings. The study may shed light on possible mechanisms of treatment resistance in EGFR trials and point to the expression of ectodomain EGFR isoforms as a novel and well-needed biomarker of relapse for this group of patients.
The patients were treated at the Radium Hospital and clinical collaborators were Gunnar B. Kristensen and the radiotherapy team at the section for Gynecological Oncology. Collaborators in statistics and bioinformatics were Marit Holden at the Norwegian Computing Center and Trevor Clancy at Department of Tumorbiology.
Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node-Negative Cervical Cancer.
Halle C, Lando M, Svendsrud DH, Clancy T, Holden M, Sundfør K, Kristensen GB, Holm R, Lyng H.
Clin Cancer Res. 2011 Aug 9.
Highlight article: EGFR Ectodomain Isoforms Predict Cervical Cancer Outcome
Heidi Lyngs project group
From major journals, first or last author from the Institute for Cancer Research
Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen
Mol Oncol (in press)
Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
Mol Syst Biol, 17 (3), e9526
Uptake of hysterectomy and bilateral salpingo-oophorectomy in carriers of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report
Eur J Cancer, 148, 124-133 (in press)